2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06B.05 Ultra-Stat Idylla EGFR Testing for Non-Small Cell Lung Carcinomas: Patient Selection and Impact on Clinical Outcomes

EP.06B.05 Ultra-Stat Idylla EGFR Testing for Non-Small Cell Lung Carcinomas: Patient Selection and Impact on Clinical Outcomes

Back to course

Pdf Summary

The study titled "Ultra-Stat Idylla EGFR Testing for Non-Small Cell Lung Carcinomas: Patient Selection and Impact on Clinical Outcomes," led by Kate Fitzsimmons and colleagues from the University of British Columbia, investigates the utilization and clinical impact of the rapid Idylla EGFR testing in NSCLC patients. EGFR-targeted therapy eligibility is determined through molecular testing, with the standard practice in British Columbia being the multi-gene Focus Panel. However, for urgent cases, the Idylla test offers rapid results and potential treatment advantages.<br /><br />Objectives of the study include analyzing patient demographics selected for the Idylla test, comparing EGFR mutation positivity rates with those detected by the Focus panel, and assessing the effect of rapid testing on clinical outcomes. The study collected data from requests made between February 2022 and March 2024, including a comparison with Focus panel requests from May 2021 to February 2024.<br /><br />Results indicated that most Idylla Tests were ordered by medical oncologists for outpatients who were likely to be female, Asian, or non-smokers, demographic features linked to EGFR mutations. The Idylla test demonstrated a higher EGFR mutation positivity rate (71.9%) compared to the Focus panel (19.6%), especially among Asian patients, which was statistically significant. The rapid turnaround time of Idylla allowed for earlier treatment initiation (median time of 1 day) compared to the Focus panel (10 days), which improved overall survival in patients with detected EGFR mutations.<br /><br />The study concludes that the Idylla test enables quick identification of EGFR mutations, facilitating timely targeted treatment and improving patient survival outcomes. The findings suggest the potential for using patient demographics, particularly race, in guiding EGFR testing approaches, supporting the development of decision aids for testing modality selection.

Asset Subtitle

Kate Fitzsimmons

Meta Tag

Speaker Kate Fitzsimmons

Topic Pathology and Biomarkers

Keywords

Idylla EGFR testing

non-small cell lung carcinoma

NSCLC

clinical outcomes

EGFR mutations

rapid testing

patient demographics

molecular testing

targeted therapy

survival outcomes